Big Pharma’s Highest-Paid CEOs:

Executive pay in Big Pharma is never just about salary. It is a reflection of market pressure, shareholder expectations, drug launches, pipeline performance, and how successfully a company can convince investors that its strategy is working.

Fierce Pharma’s 2025 ranking of the highest-paid Big Pharma CEOs highlights exactly that. But it is important to clarify one key point: these figures are not base salaries alone. They represent total compensation packages, which often include stock awards, performance incentives, bonuses, retirement benefits, and other forms of executive compensation.

That distinction matters. In 2025, the top pharma CEOs were not simply earning multimillion-dollar salaries. Much of their reported compensation came through equity-based awards tied to company performance and long-term shareholder value.

Among the headline figures:

CEO	Company	2025 total compensation
David Ricks	Eli Lilly	$36.7 million
Joaquin Duato	Johnson & Johnson	$32.6 million
Robert Michael	AbbVie	$32.5 million
Daniel O’Day	Gilead Sciences	$28.4 million
Albert Bourla	Pfizer	$27.6 million

The base salaries themselves were far lower, generally ranging from around $1.6 million to $1.8 million. The difference came from stock awards, option awards, bonuses, and other compensation structures.

At first glance, these headline numbers are striking. But the bigger story is what sits behind them.

For Lilly, David Ricks’ position at the top reflects the company’s extraordinary momentum in diabetes and obesity treatments, particularly around Mounjaro and Zepbound. The GLP-1 market has reshaped the pharmaceutical landscape, and Lilly has become one of the clearest examples of how a single therapeutic area can transform company valuation, investor confidence, and executive reward.

Johnson & Johnson’s Joaquin Duato also remained near the top of the list, with a 2025 package of $32.6 million. His leadership comes during a major transition period for J&J, following the separation of its consumer health business and a continued push to strengthen its pharmaceutical and medtech growth engines.

AbbVie’s Robert Michael was one of the most notable movers, with total compensation reaching $32.5 million. His rise reflects AbbVie’s efforts to move beyond Humira and prove that newer growth drivers such as Skyrizi and Rinvoq can carry the company through its post-Humira era.

Gilead’s Daniel O’Day and Pfizer’s Albert Bourla rounded out the top five, both leading companies navigating major strategic shifts. Gilead continues to lean on its HIV portfolio while expanding in oncology, while Pfizer is working through restructuring, post-COVID recalibration, and the ongoing pressure to rebuild future growth.

The numbers make one thing clear: Big Pharma boards are rewarding leaders not only for what happened in 2025, but for the future value they are expected to create. Stock awards and long-term incentives are designed to align CEOs with shareholders, but they also turn executive compensation into a public signal of confidence in a company’s strategy.

Still, the scale of executive pay continues to raise difficult questions. Pharma companies operate in an environment shaped by drug pricing debates, access challenges, patent cliffs, regulatory scrutiny, and growing public pressure around healthcare affordability. When CEO compensation climbs into the tens of millions, it inevitably becomes part of a broader conversation about value: value for shareholders, value for patients, and value for healthcare systems.

The 2025 ranking shows an industry in transition. Companies with strong growth stories, successful launches, and credible pipeline strategies are rewarding their leaders accordingly. But the same figures also remind us that pharma leadership today is judged not only by financial performance, but by how companies navigate innovation, access, trust, and long-term sustainability. In Big Pharma, executive pay is more than a number. It is a signal of where the industry believes its future value will come from.

G-Med excels in HCP marketing by blending digital innovation with data-driven insights, creating an effective platform for reaching healthcare professionals, offering various advertising solutions. By using G-Med to engage HCPs, share data reports, and explore innovative channels, marketers can deliver targeted, impactful messages that foster strong connections. G-Med’s approach ensures that each campaign is tailored, scientifically rigorous, and effective, aligning perfectly with the best practices for successful HCP marketing.   

Contact us today to learn more: Contact@g-med.com